MedTrace Logo

Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

NCT06932861 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-04-22

No results posted yet for this study

Summary

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Conditions

  • Rhabdomyosarcoma

Interventions

BIOLOGICAL

mRNA Tumor Vaccine Therapy

personalized mRNA vaccines

Sponsors & Collaborators

  • Xinxin Zhang

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2027-05-01
Completion
2028-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06932861 on ClinicalTrials.gov